Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.47 |
| ▸ | HTR2A | P28223 | 6/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 7/20 | 0.46 |
| ▸ | HTR2B | P41595 | 6/20 | 0.46 |
| ▸ | MAOB | P27338 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1388099 | 0.79 | SIGMAR1 (0.55) | SIGMAR1HTR2AHTR2CHTR2B | |
| SCHEMBL11242609 | 0.78 | SIGMAR1 (0.49) | SIGMAR1HTR2AHTR2CHTR2B | |
| SCHEMBL11308894 | 0.78 | SIGMAR1 (0.41) | SIGMAR1HTR2AMEN1KMT2AHTR2C | |
| SCHEMBL11294227 | 0.78 | SIGMAR1 (0.47) | SIGMAR1HTR2AHTR2CHTR2B | |
| SCHEMBL11318314 | 0.78 | SIGMAR1 (0.41) | SIGMAR1HTR2AHTR2CHTR2B | |
| SCHEMBL7552511 | 0.78 | KDM1A (0.42) | SIGMAR1HTR2AMEN1KMT2AHTR2C | |
| SCHEMBL11287871 | 0.77 | SIGMAR1 (0.41) | SIGMAR1HTR2AHTR2CHTR2B | |
| SCHEMBL13050844 | 0.77 | SIGMAR1 (0.47) | SIGMAR1HTR2AHTR2CHTR2B | |
| SCHEMBL13050822 | 0.77 | HTR2C (0.54) | SIGMAR1HTR2C | |
| SCHEMBL13050838 | 0.77 | HTR2C (0.54) | SIGMAR1HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100292292-A1 | Treatment of Neurodegenerative Diseases Using Indatraline Analogs | LINK MEDICINE CORPORATION (US) | 2010-11-18 | — | — | US | disclosed |
| US-20100292292-A1 | Treatment of Neurodegenerative Diseases Using Indatraline Analogs | LINK MEDICINE CORPORATION (US) | 2010-11-18 | — | — | US | disclosed |
| WO-2009036275-A1 | TREATMENT OF NEURODEGENERATIVE DISEASES USING INDATRALINE ANALOGS | LINK MEDICINE CORPORATION (US) | 2009-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292292-A1 | Treatment of Neurodegenerative Diseases Using Indatraline Analogs | HTT, SNCA, PARK7 | SIGMAR1 980/4885HTR2A 62/4885MEN1 2809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.